Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12606000429550
ACTRN12606000429550
Not yet recruiting
Not Applicable

A single-blind randomised phase IV study to evaluate the effectiveness of the AMBU Aura-once disposable Laryngeal Mask against the Laryngeal Mask Airway -unique wih respect to sealing pressure and ease of use for airway maintenance during spontaneous ventilation general anaesthesia

Royal Melbourne Hospital - Department of Anaesthesia and Pain Management0 sites100 target enrollmentOctober 4, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAirway maintenance during anaesthesiaAnaesthesiology - Other anaesthesiologyRespiratory -

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Airway maintenance during anaesthesia
Sponsor
Royal Melbourne Hospital - Department of Anaesthesia and Pain Management
Enrollment
100
Status
Not yet recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 4, 2006
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Royal Melbourne Hospital - Department of Anaesthesia and Pain Management

Eligibility Criteria

Inclusion Criteria

  • •Adults who are undergoing general anaesthesia suitable for a LMA.

Exclusion Criteria

  • •Recognised non suitability for supraglottic airway usage.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
To evaluate the Immunogenicity and Safety of Inactivated Japanese encephalitis vaccine
CTRI/2020/02/023128Bharat Biotech International Ltd500
Completed
Phase 4
A Phase IV, monocentric, clinical trial to evaluate and compare the number of nicks and cuts among three different shaving systems on healthy Indian men.
CTRI/2011/07/001890Procter and Gamble50
Completed
Phase 4
Parenting Eating and Activity for Child HealthChild overweightDiet and Nutrition - Other diet and nutrition disorders
ACTRN12606000120572Flinders University168
Active, not recruiting
Phase 1
Elective rituximab in TTPAcquired thrombotic thrombocytopenic purpuraTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2017-001117-86-GBniversity College London52
Active, not recruiting
Phase 1
A study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK)'s Infanrix hexa vaccine (DTPa HBV IPV/Hib) versus MCM Vaccine BV's Vaxelis vaccine (DTaP5 HBV IPV Hib) in healthy infants and toddlers
EUCTR2019-002988-10-ITGLAXOSMITHKLINE BIOLOGICALS500